

Nuedexta® Effective in Treating Pseudobulbar Affect

Results of the PRISM II study by Avanir Pharmaceuticals, Inc., in *BMC Neurology* demonstrated significant improvement of pseudobulbar affect (PBA) following treatment with Nuedexta® (dextromethorphan hydrobromide/quinidine sulfate) capsules in patients with Alzheimer's disease and other dementias, stroke, and traumatic brain injury.

PRISM II was an open-label, multicenter study that included 367 participants who received



© 2016 Shutterstock.com

Nuedexta for 90 days. Results included:

- Center for Neurologic Study–Lability Scale scores improved significantly from a mean of 20.5 at baseline to 12.8 ($p < 0.001$) at the 90-day endpoint, which is consistent with results seen with Nuedexta in the Phase III trial.

ElderCheck Now App Helps Caregivers Obtain Updated Health Information

The ElderCheck Now app aims to help caregivers obtain updated health information of the older adults they monitor by leveraging new technology available in the latest smart devices. Caregivers can send secure check-ins to older adults, who can respond through a simplified two-button interface on Apple Watch® or iPhone®.

Taking advantage of features unique to iPhone and Apple Watch, the ElderCheck Now app creates an easy way for older adults to pass regular updates in less time than it would take to text or make a phone call. Where texting “I’m OK” fails to convey the full levity of a potential health situation, the app’s “I’m OK” or “Call Me” status updates a caregiver while sending important heart rate information and GPS location, and presents a button to quickly return a phone call.

Source. “New App Connects Caregivers to Updated Health and Well-Being Information for the Elders They Care for.” (2016, June 16). Retrieved June 23, 2016, from <http://prn.to/299bQ6w>.



© 2016 Shutterstock.com

- PBA episodes were reduced by 72.6% ($p < 0.001$) compared to baseline at the 90-day endpoint. PBA episode counts over the 7 days prior to study visit decreased from a median of 12 at baseline to two at the 90-day endpoint; 35.5% of patients experienced no PBA episodes at the 90-day endpoint.

- Clinicians rated 77% of patients as “very much improved” or “much improved” with respect

to PBA symptoms, as well as 72% of participants using the Clinical Global Impression of Change and Patient (or Caregiver) Global Impression of Change.

Source. “Nuedexta® Effective for Pseudobulbar Affect (PBA) in Patients with Alzheimer's Disease and other Dementias, Stroke and Traumatic Brain Injury.” (2016, June 8). Retrieved June 23, 2016, from <http://prn.to/28Zaivr>.

doi:10.3928/00989134-20160713-02